Thoroughbred Financial Services LLC Buys 1,052 Shares of Illumina, Inc. (NASDAQ:ILMN)

Thoroughbred Financial Services LLC lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 65.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,662 shares of the life sciences company’s stock after purchasing an additional 1,052 shares during the quarter. Thoroughbred Financial Services LLC’s holdings in Illumina were worth $355,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. WCM Investment Management LLC boosted its holdings in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after acquiring an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Illumina by 0.8% in the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock worth $454,617,000 after purchasing an additional 27,618 shares in the last quarter. Geode Capital Management LLC grew its position in Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after purchasing an additional 48,018 shares during the period. Norges Bank acquired a new position in Illumina during the fourth quarter worth $228,714,000. Finally, Pictet Asset Management Holding SA lifted its stake in shares of Illumina by 245.7% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company’s stock valued at $158,011,000 after buying an additional 840,423 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Royal Bank of Canada decreased their target price on shares of Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday, March 12th. Citigroup decreased their price objective on Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Piper Sandler raised their target price on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Canaccord Genuity Group decreased their price target on Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, March 11th. Finally, Robert W. Baird dropped their price objective on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Stock Down 3.0 %

ILMN opened at $74.16 on Monday. Illumina, Inc. has a 12 month low of $70.64 and a 12 month high of $156.66. The company has a market cap of $11.75 billion, a PE ratio of -9.66, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a 50 day moving average of $96.82 and a 200 day moving average of $125.02.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.